IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
IGC Pharma added the Icahn School of Medicine at Mount Sinai as a clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. The trial is approximately 80% complete in terms of participant enrollment, with the company now focused on database lock and topline analysis.
Key figures
- Drug Name
- IGC-AD1
- Phase Of Trial
- Phase 2
- Enrollment progress
- 80%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.